{"entity":{"id":"nct06149559","kind":"trial","name":"A Study of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe Generalized Myasthenia Gravis","aka":[],"tldr":"A phase 2/3 trial of rozanolixizumab in childhood cancers, run by UCB Biopharma SRL, active and no longer recruiting.","summary":"A Study of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe Generalized Myasthenia Gravis is a phase 2/3 interventional study registered as NCT06149559 by UCB Biopharma SRL, with 14 participants enrolled, started 2024-06-14 and due to reach its primary completion in 2026-10-05. Interventions recorded: rozanolixizumab.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06149559","url":"https://clinicaltrials.gov/study/NCT06149559"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["childhood-cancers"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["ucb"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06149559","phase":"2/3","setting":"An Open-label, Single-arm Study Evaluating the Activity, Safety, and Pharmacokinetics of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe Generalized Myasthenia Gravis","sponsor":"UCB Biopharma SRL","enrolled":14,"outcomes":[]},"route":"/trials/nct06149559/","neighbours":{"cancer":[{"id":"childhood-cancers","kind":"cancer","name":"Childhood cancers (all types)","route":"/cancers/childhood-cancers/"}],"company":[{"id":"ucb","kind":"company","name":"UCB","route":"/companies/ucb/"}]}}